With the increasing frequency of metabolic disorders in the western population, dual FXR antagonistic/GPBAR1 agonistic potency represents an interesting synergistic pharmacological intervention and therapeutic application to this issue. This evidence concerns the gene NR1H4 and Other metabolic disease.